Home
NXL
NXL News

Latest Nexalin Technology Inc. (NXL) News on February 23, 2025

MT Newswires

5 days ago

Nexalin Technology Says Halo Clarity Headset Clinical Testing Gets UCSD Institutional Review Board Approval

Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment

GlobeNewswire

5 days ago

Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment

Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition

GlobeNewswire

13 days ago

Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition

Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

GlobeNewswire

20 days ago

Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

Argus Research

a month ago

Daily – Vickers Top Buyers & Sellers for 01/27/2025

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23

GlobeNewswire

a month ago

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23

Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025

GlobeNewswire

a month ago

Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025

Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic

GlobeNewswire

2 months ago

Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic

MT Newswires

2 months ago

Nexalin Files for Potential Stock Sale by Maxim Partners

New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market

GlobeNewswire

3 months ago

New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market

Nexalin Technology CEO Provides Letter to Shareholders

GlobeNewswire

3 months ago

Nexalin Technology CEO Provides Letter to Shareholders

Is Nexalin Technology (NASDAQ:NXL) In A Good Position To Invest In Growth?

Simply Wall St.

3 months ago

Is Nexalin Technology (NASDAQ:NXL) In A Good Position To Invest In Growth?

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th

GlobeNewswire

4 months ago

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th

MT Newswires

4 months ago

Nexalin Technology Regains Nasdaq Compliance Over Minimum Bid Price; Shares Rise

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

GlobeNewswire

4 months ago

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESSWIRE

4 months ago

LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease

GlobeNewswire

4 months ago

Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease

EXCLUSIVE: Nexalin Technology Says New Data Confirms Investigational Non-Invasive Neurostimulation Device Improves Cognitive Function, Restores Brain Activity in Alzheimer's Patients (UPDATED)

Benzinga

4 months ago

EXCLUSIVE: Nexalin Technology Says New Data Confirms Investigational Non-Invasive Neurostimulation Device Improves Cognitive Function, Restores Brain Activity in Alzheimer's Patients (UPDATED)

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESSWIRE

4 months ago

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nexalin trials Halo neurostimulation device in traumatic brain injury

Clinical Trials Arena

4 months ago

Nexalin trials Halo neurostimulation device in traumatic brain injury

MT Newswires

4 months ago

Sector Update: Health Care Stocks Softer Late Afternoon

MT Newswires

4 months ago

Nexalin Technology Shares Rise After Clinical Trial Set for Halo Headset in Traumatic Brain Injuries

Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA

GlobeNewswire

4 months ago

Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA

Mixed results for Nexalin’s transcranial alternating current stimulation trial

Medical Device Network

4 months ago

Mixed results for Nexalin’s transcranial alternating current stimulation trial

Mixed results for Nexalin’s transcranial alternating current stimulation trial

Clinical Trials Arena

4 months ago

Mixed results for Nexalin’s transcranial alternating current stimulation trial

New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients

GlobeNewswire

4 months ago

New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients

EXCLUSIVE: Nano-Cap Nexalin's Drug-Free Alternative For Alzheimer's Shows Improved Memory, Cognitive Function In Small Study

Benzinga

4 months ago

EXCLUSIVE: Nano-Cap Nexalin's Drug-Free Alternative For Alzheimer's Shows Improved Memory, Cognitive Function In Small Study

Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs

GlobeNewswire

4 months ago

Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs

Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment

GlobeNewswire

6 months ago

Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment

Nexalin Technology Second Quarter 2024 Earnings: US$0.17 loss per share (vs US$0.11 loss in 2Q 2023)

Simply Wall St.

6 months ago

Nexalin Technology Second Quarter 2024 Earnings: US$0.17 loss per share (vs US$0.11 loss in 2Q 2023)

Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESSWIRE

7 months ago

Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery

GlobeNewswire

7 months ago

Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery

MT Newswires

7 months ago

Nexalin Technology Says It Regains Nasdaq Compliance Following Stock Offering; Shares Fall

MT Newswires

8 months ago

Nexalin Technology Completes $5.3 Million Share Offering

Nexalin Technology Announces Closing of $5.2 Million Public Offering

GlobeNewswire

8 months ago

Nexalin Technology Announces Closing of $5.2 Million Public Offering

MT Newswires

8 months ago

Top Midday Decliners

MT Newswires

8 months ago

Top Premarket Decliners

Nexalin Technology Announces Pricing of $5.2 Million Public Offering

GlobeNewswire

8 months ago

Nexalin Technology Announces Pricing of $5.2 Million Public Offering

Nexalin’s deep brain stimulation add-on therapy alleviates depression

Medical Device Network

8 months ago

Nexalin’s deep brain stimulation add-on therapy alleviates depression

Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal

GlobeNewswire

8 months ago

Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal

Nexalin secures US patent for Alzheimer’s deep-brain stimulation device

Medical Device Network

8 months ago

Nexalin secures US patent for Alzheimer’s deep-brain stimulation device

Nano-Cap Nexalin Technology Secures US Patent For Stimulation Device For Alzheimer's And Dementia Treatment

Benzinga

8 months ago

Nano-Cap Nexalin Technology Secures US Patent For Stimulation Device For Alzheimer's And Dementia Treatment

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia

GlobeNewswire

8 months ago

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia

Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESSWIRE

8 months ago

Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)

GlobeNewswire

8 months ago

Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)

MicroCap Rodeo’s Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies

ACCESSWIRE

9 months ago

MicroCap Rodeo’s Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies

Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th

GlobeNewswire

9 months ago

Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th

FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device

GlobeNewswire

9 months ago

FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device

Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts

GlobeNewswire

9 months ago

Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts

Nexalin Technology First Quarter 2024 Earnings: US$0.14 loss per share (vs US$0.10 loss in 1Q 2023)

Simply Wall St.

9 months ago

Nexalin Technology First Quarter 2024 Earnings: US$0.14 loss per share (vs US$0.10 loss in 1Q 2023)

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23

GlobeNewswire

9 months ago

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23

MT Newswires

10 months ago

Nexalin Technology Regains Compliance With Nasdaq Listing Requirement

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

GlobeNewswire

10 months ago

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

Nexalin Technology CEO Provides Letter to Shareholders

GlobeNewswire

10 months ago

Nexalin Technology CEO Provides Letter to Shareholders

Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing

GlobeNewswire

10 months ago

Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing

Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device

GlobeNewswire

a year ago

Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device

Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device

News Direct

a year ago

Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device

Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board

GlobeNewswire

a year ago

Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board

Nexalin Technology Full Year 2023 Earnings: US$0.63 loss per share (vs US$0.30 loss in FY 2022)

Simply Wall St.

a year ago

Nexalin Technology Full Year 2023 Earnings: US$0.63 loss per share (vs US$0.30 loss in FY 2022)

Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego

GlobeNewswire

a year ago

Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego

Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology

GlobeNewswire

a year ago

Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology

Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”

GlobeNewswire

a year ago

Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”

Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia

GlobeNewswire

a year ago

Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia

Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device

GlobeNewswire

a year ago

Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device

Hempacco to Exhibit at the 2024 Tobacco Plus Expo (TPE) in Las Vegas, Booth #25086

Newsfile

a year ago

Hempacco to Exhibit at the 2024 Tobacco Plus Expo (TPE) in Las Vegas, Booth #25086

Gulf Resources Announces the Completion of the Flood Prevention Project

GlobeNewswire

a year ago

Gulf Resources Announces the Completion of the Flood Prevention Project

Business Wire

a year ago

Innventure LLC and Learn CW Investment Corporation Announce Filing of Registration Statement on Form S-4 in Connection With Proposed Business Combination

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System

GlobeNewswire

a year ago

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System

Business Wire

a year ago

Learn CW Investment Corporation Extends Period to Consummate Initial Business Combination

A Record Revenue Year for Maris-Tech.

GlobeNewswire

a year ago

A Record Revenue Year for Maris-Tech.

Nexalin Technology Unveils Next-Generation HALO™ Clarity

GlobeNewswire

a year ago

Nexalin Technology Unveils Next-Generation HALO™ Clarity

10 Supplements for Longevity and Antiaging: Expert Recommendations

Insider Monkey

a year ago

10 Supplements for Longevity and Antiaging: Expert Recommendations

Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT

GlobeNewswire

a year ago

Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT

Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression

GlobeNewswire

a year ago

Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression

Thomson Reuters StreetEvents

a year ago

Q4 2023 Good Times Restaurants Inc Earnings Call

Associated Press Finance

a year ago

Good Times Restaurants: Fiscal Q4 Earnings Snapshot

Good Times Restaurants Reports Results for the Fourth Quarter and Fiscal Year Ended September 26, 2023

Business Wire

a year ago

Good Times Restaurants Reports Results for the Fourth Quarter and Fiscal Year Ended September 26, 2023

Aadi Bioscience, Inc. (NASDAQ:AADI) is definitely on the radar of institutional investors who own 39% of the company

Simply Wall St.

a year ago

Aadi Bioscience, Inc. (NASDAQ:AADI) is definitely on the radar of institutional investors who own 39% of the company

HeartCore Implements New Function to Enhance its Market Leading CMS Platform

GlobeNewswire

a year ago

HeartCore Implements New Function to Enhance its Market Leading CMS Platform

Here's Why We're Watching BriaCell Therapeutics' (TSE:BCT) Cash Burn Situation

Simply Wall St.

a year ago

Here's Why We're Watching BriaCell Therapeutics' (TSE:BCT) Cash Burn Situation

MoneyHero to Announce Third Quarter 2023 Financial Results

GlobeNewswire

a year ago

MoneyHero to Announce Third Quarter 2023 Financial Results

CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction

GlobeNewswire

a year ago

CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction

Business Wire

a year ago

Learn CW Investment Corporation Receives Noncompliance Notification from the New York Stock Exchange Due to Delayed Form 10-Q Filing

Is Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Trading At A 24% Discount?

Simply Wall St.

a year ago

Is Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Trading At A 24% Discount?

GlobeNewswire

a year ago

Presidio Property Trust Announces Update of Share Repurchase Program

Star Equity Holdings, Inc. Declares Cash Dividend of $0.25 Per Share of 10% Series A Cumulative Perpetual Preferred Stock

GlobeNewswire

a year ago

Star Equity Holdings, Inc. Declares Cash Dividend of $0.25 Per Share of 10% Series A Cumulative Perpetual Preferred Stock

AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference

Business Wire

a year ago

AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference

GlobeNewswire

a year ago

Presidio Property Trust, Inc. Announces Earnings for the Quarter Ended September 30, 2023

ClearSign Technologies Corporation Provides Third Quarter 2023 Update

PR Newswire

a year ago

ClearSign Technologies Corporation Provides Third Quarter 2023 Update

Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies

Zacks

a year ago

Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies

ATA Creativity Global Reports 2023 Third Quarter Financial Results

GlobeNewswire

a year ago

ATA Creativity Global Reports 2023 Third Quarter Financial Results

ENGlobal Announces Third Quarter 2023 Financial and Operating Results

ACCESSWIRE

a year ago

ENGlobal Announces Third Quarter 2023 Financial and Operating Results

JOANN Launches Early Black Friday Deals to Help Customers Beat the Holiday Rush

GlobeNewswire

a year ago

JOANN Launches Early Black Friday Deals to Help Customers Beat the Holiday Rush

Business Wire

a year ago

Learn CW Investment Corporation Announces Extension to Period to Consummate Initial Business Combination

PR Newswire

a year ago

AVALON HOLDINGS CORPORATION ANNOUNCES THIRD QUARTER RESULTS

Share on Social Networks: